{"id":"NCT03965962","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults","officialTitle":"Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free in Comparison With Verorab® and Imovax® Rabies, in a Simulated Rabies Post-exposure Regimen in Healthy Adults in France","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-07-01","primaryCompletion":"2020-12-22","completion":"2021-07-01","firstPosted":"2019-05-29","resultsPosted":"2022-03-11","lastUpdate":"2022-07-19"},"enrollment":640,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Rabies (Healthy Volunteers)"],"interventions":[{"type":"BIOLOGICAL","name":"VRVg-2","otherNames":[]},{"type":"BIOLOGICAL","name":"Purified Inactivated Rabies Vaccine","otherNames":["Verorab®"]},{"type":"BIOLOGICAL","name":"Human Diploid Cell Vaccine (HDCV)","otherNames":["IMOVAX® Rabies"]},{"type":"BIOLOGICAL","name":"Rabies immune globulin (human)","otherNames":["IMOGAM® Rabies-HT"]}],"arms":[{"label":"Group 1: VRVg-2 + HRIG","type":"EXPERIMENTAL"},{"label":"Group 2: Verorab + HRIG","type":"ACTIVE_COMPARATOR"},{"label":"Group 3: Imovax Rabies + HRIG","type":"ACTIVE_COMPARATOR"},{"label":"Group 4: VRVg-2","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo demonstrate that Purified Vero Rabies Vaccine - Serum Free Vaccine generation 2 (VRVg-2) was non-inferior to Verorab and Imovax Rabies vaccines when co-administered with human rabies immunoglobulin (HRIG), in terms of proportion of participants achieving a rabies virus neutralizing antibody (RVNA) titer greater than or equal to (\\>=) 0.5 international units per milliliter (IU/mL) at Day 28, i.e., 14 days after the fourth vaccine injection.\n\nSecondary Objective:\n\n* To describe the safety profile of VRVg-2 versus Verorab and Imovax Rabies vaccines when co-administered with HRIG, as well as that of VRVg-2, after each vaccine injection.\n* To demonstrate that the proportion of participants in the VRVg-2 + HRIG group achieving an RVNA titer \\>= 0.5 IU/mL at Day 28 was at least 95 percent (%).\n* To describe the immune response induced by VRVg-2 versus Verorab and Imovax Rabies vaccines when co-administered with HRIG, as well as that induced by VRVg-2, at Day 14 (7 days after the third injection), at Day 28 (14 days after the fourth injection) and at Day 42 (14 days after the last injection).","primaryOutcome":{"measure":"Percentage of Participants With Rabies Virus Neutralizing Antibody (RVNA) Titers Greater Than or Equal to (>=) 0.5 International Units Per Milliliter (IU/mL)-Non-Inferiority Analysis","timeFrame":"Day 28","effectByArm":[{"arm":"Group 1 VRVg-2+HRIG","deltaMin":99.6,"sd":null},{"arm":"Group 2 Verorab+HRIG","deltaMin":100,"sd":null},{"arm":"Group 3 Imovax Rabies+HRIG","deltaMin":98.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":15},"locations":{"siteCount":2,"countries":["France"]},"refs":{"pmids":["38478634"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":320},"commonTop":["Injection Site Pain","Headache","Myalgia","Malaise","Fatigue"]}}